Britain's health regulator said on Wednesday it has approved Japan-based Astellas Pharma's (4503.T), opens new tab therapy to treat a type of gastric cancer.
The monoclonal antibody, which can attach itself to certain cancer cells and destroy them, was approved in combination with a standard chemotherapy for adults with cancer in the stomach or the junction where the oesophagus joins the stomach.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,